Xiaobin Wu
Equibles does not estimate personal net worth.
About Xiaobin Wu
Xiaobin Wu was last confirmed as COO at BeOne Medicines Ltd. (ONC) in a filing dated April 27, 2023. Xiaobin Wu has spoken on 4 earnings calls across 1 company, most recently for BeOne Medicines Ltd. on February 26, 2026. The companies whose calls Xiaobin Wu spoke on are classified in the Healthcare sector.
Xiaobin Wu on recent calls
“So, China Sauron approved beginning of this year, 2026, and we launched so quickly after that approval. And since launch, this is about six weeks.”
“In Europe, we grow for BRUKINSA tremendously, so close to 70%. And we notified in Europe in some countries like Germany and Austria that AMPLIFY launched. We don't see much excitement among the market, and the company may actively switch the mono acala to AMPLIFY.”
“As Aaron mentioned, the U.S. is our biggest revenue driver, achieving $685 million with a growth rate of 43%. China is the second biggest contributor, growing 23%.”
“Our global development strategy and the Board trial design have resulted in the broadest label and widespread coverage for BRUKINSA and TEVIMBRA. We have achieved significant global reach in a short period of time and have now treated over 1.7 million cancer patients with our therapies.”
Affiliation history
-
Start not stated–2023-04-27
Last confirmed by a filing; no departure on record
-
BeOne Medicines Ltd. (ONC)
Proxy statement
Start not stated–2020-04-28
Last confirmed by a filing; no departure on record